DUBLIN--(BUSINESS WIRE)--The "Dendritic Cancer Cell Therapy- Pipeline Insights, 2018" report has been added to ResearchAndMarkets.com's offering.
This report outlays comprehensive insights of present scenario and growth prospects across Dendritic Cancer Cell Therapy.
A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type.
This report provides detailed analysis of 25+ products with more than 15+ companies involved. Some of the emerging products include DCVax-L of Northwest Biotherapeutics, CreaVax of Creagene, and Rocapuldencel-T of Argos Therapeutics.
Products covered by Phase
- Phase III, Phase II, Phase I
- IND
- Pre-clinical & Discovery
- Inactive (Dormant & Discontinued)
Overview of pipeline development activities for Dendritic Cancer Cell Therapy
- Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
- Therapeutic segmentation of products for Dendritic Cancer Cell Therapy.
-
The report comprises of comparative pipeline therapeutics assessment
by development stage, therapy type, molecule type, and administration
route across this mechanism.
Scope
- Provides an overview of therapeutic pipeline activity for Dendritic Cancer Cell Therapy across the complete product development cycle including all clinical and non-clinical stages
- It comprises of detailed profiles of Dendritic Cancer Cell Therapy therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
- Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
- Coverage of dormant and discontinued pipeline projects across Dendritic Cancer Cell Therapy
Companies Featured
- Argos Therapeutics
- Asterias Pharmaceuticals
- Bellicum Pharmaceuticals
- CiMaas
- Creagene
- DCPrime
- Diavacs
- Enonchian
- Immunicum
- ImmunoCellular Therapeutics
- Kiromic Biopharma
- Medigene
- MedImmune
- MicroVAX
- Northwest Biotherapeutics
- Orbis
- Sotio
- Tella
- Vaxil Bio Therapeutics
Key Topics Covered
- Executive Summary
- Overview
- Introduction
- Mechanism of Action
- Types of Cancer Treated
- Dendritic Cancer Cells vs Other Therapies
- Side effects of Dendritic Cancer Cell Therapy
- Limitations of Dendritic Cancer Cell Therapy
- Conclusion and Future Perspectives
- Pipeline Therapeutics (Active Products)
- Pipeline Therapeutics (Inactive Products)
- Comparative Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- CreaVax: Creagene
- Product Description
- Research and Development
- Product Development Activities
- The list continues.
- Mid Stage Products (Phase II)
- Comparative Analysis
- BSK-01: Kiromic Biopharma
- Product Description
- Research and Development
- Product Development Activities
- The list continues..
- Early Stage Products (Phase I & IND)
- Comparative Analysis
- Pre-clinical and Discovery Stage Products
- Comparative Analysis
- Therapeutic Assessment: Active Products
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Inactive Products
- Comparative Analysis
For more information about this report visit https://www.researchandmarkets.com/research/xnqvjk/dendritic_cancer?w=4
